Stock comparison
Rigel Pharmaceuticals
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
RIGL
Rigel Pharmaceuticals
Market cap
$536.75M
Sector
Healthcare
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | RIGL | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 47D | 72B | RMD |
| Benjamin Graham | 34F | 75B | RMD |
| Philip Fisher | 54C | 75B | RMD |
| Peter Lynch | 54C | 58C | RMD |
| Joel Greenblatt | 48D | 47D | RIGL |
| Charlie Munger | 62D | 69B | RMD |
| Terry Smith | 61C | 73B | RMD |
Side-by-side metrics
| Metric | RIGL | RMD |
|---|---|---|
| Market cap | $536.75M | $30.18B |
| P/E (TTM) | 1.4x | 19.6x |
| EV/EBIT | 4.3x | 17.1x |
| ROIC (TTM) | 27.96% | 19.63% |
| Gross margin | 93.39% | 61.69% |
| Net margin | 121.51% | 27.44% |
| Revenue CAGR 5y | 18.5% | 12.64% |
| EPS CAGR 5y | - | 30.73% |
| Debt / Equity | 0.1x | 0.1x |
| Dividend yield | 0.0% | 1.14% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
RIGL leads on
- P/E (TTM)1.4xvs 19.6x+93%
- Net margin121.51%vs 27.44%+77%
- EV/EBIT4.3xvs 17.1x+75%
- Gross margin93.39%vs 61.69%+34%
RMD leads on
- Dividend yield1.14%vs 0.0%+100%
- Market cap$30.18Bvs $536.75M+98%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.